Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Cet article présente une mise à jour des recommandations du "National Comprehensive Cancer Network" concernant la prise en charge thérapeutique d'un adénocarcinome du pancréas primitif, métastatique ou récidivant
In 2026, an estimated 67,530 people will be diagnosed with pancreatic cancer, and approximately 52,740 people will die from the disease in the United States.1 Pancreatic cancer is the third leading cause of cancer-related death in the United States.1 In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma, the diagnosis and management of adenocarcinomas of the exocrine pancreas are discussed; neuroendocrine tumors are not included (please see the NCCN Guidelines for Neuroendocrine and Adrenal Tumors, available at NCCN.org). For clinical purposes, most NCCN Member Institutions use a clinical classification system based mainly on results of presurgical imaging studies. For patients with confirmed tumors on imaging, disease is classified as: 1) resectable; 2) borderline resectable (ie, tumors that are involved with nearby structures such that there would be a high chance of an R1 resection if surgery were performed up-front); 3) locally advanced (ie, tumors that are involved with nearby structures to an extent that renders them unresectable despite the absence of evidence of metastatic disease), for which the Panel recommends that the patient be referred to a tertiary cancer center for second opinion about resectability; or 4) metastatic. This classification is used throughout the guidelines.
Journal of the National Comprehensive Cancer Network , article en libre accès, 2026